The FDA will decide on October 1st whether or not to approve a Gilead CAR-T treatment for refractory B-cell precursor Acute Lymphoblastic Leukemia. If nothing else, this would help to promote facilities capable of offering CAR-T and that can benefit some with CLL.
I am also reposting this article that does pertain to CLL/CAR-T and I think it is worth being aware of.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.